article · Pharmaceuticals
Sulfated polysaccharide extracted from the green seaweed Codium tomentosum demonstrates potent antioxidant, anti-inflammatory, and anti-angiogenic properties. Laboratory evaluations show the polysaccharide possesses marked radical-scavenging and reducing capacity. In an animal model of carrageenan-induced paw inflammation, treatment reduced swelling, limited leukocyte migration, and re-established redox balance. The compound significantly lowered malondialdehyde levels while boosting key antioxidant enzymes, including superoxide dismutase and glutathione peroxidase, in both inflamed tissue and red blood cells. It also protected lymphocyte DNA from damage and restored normal blood parameters. Furthermore, tests on a chorioallantoic membrane model revealed that the polysaccharide curtailed the growth and branching of new blood vessels in a dose-dependent manner, supported by in silico pharmacokinetic evaluations. Together, these combined activities highlight the molecule's promise as a therapeutic anti-proliferative agent.
Uncontrolled inflammation, oxidative stress, and excessive blood vessel growth underpin many severe medical conditions, including chronic inflammatory and proliferative disorders. Identifying bioactive molecules from natural marine sources provides valuable starting points for therapeutic discovery. Showing that seaweed polysaccharides can simultaneously suppress inflammation, protect cellular DNA, and restrict abnormal vessel development provides a promising basis for developing multi-target treatments.
This work points towards applications in pharmaceutical development for anti-inflammatory, antioxidant, and anti-proliferative therapies. Target users include biotechnology firms and drug developers working on seaweed-derived bioactive compounds. Given that the findings are derived from computational evaluations, cell-free assays, and early-stage animal and membrane models, the technology is at an early discovery stage and requires extensive formulation, safety, and clinical validation before commercial adoption is feasible.
AI-generated from the published abstract. Always read the original work before citing.
The purpose of this paper was to investigate the anti-inflammatory and anti-angiogenic activities of sulfated polysaccharide from C. tomentosum (PCT) using carrageenan (CARR)-induced paw edema in a rat model and anti-vasculogenic activity on a chorioallantoic membrane assay (CAM) model. Based on in vitro tests of anti-radical, total antioxidant, and reducing power activities, PCT presents a real interest via its antioxidant activity and ability to scavenge radical species. The in vivo pharmacological tests suggest that PCT possesses anti-inflammatory action by reducing paw edema and leukocyte migration, maintaining the redox equilibrium, and stabilizing the cellular level of several pro-/antioxidant system markers. It could significantly decrease the malondialdehyde levels and increase superoxide dismutase, glutathione peroxidase, and glutathione activities in local paw edema and erythrocytes during the acute inflammatory reaction of CARR. PCT pretreatment was effective against DNA alterations in the blood lymphocytes of inflamed rats and reduced the hematological alteration by restoring blood parameters to normal levels. The anti-angiogenic activity results revealed that CAM neovascularization, defined as the formation of new vessel numbers and branching patterns, was decreased by PCT in a dose-dependent manner, which supported the in silico bioavailability and pharmacokinetic findings. These results indicated the therapeutic effects of polysaccharides from C. tomentosum and their possible use as anti-proliferative molecules based on their antioxidant, anti-inflammatory, and anti-angiogenic activities.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/ph17060672
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
